US › Healthcare

Burning Rock Biotech Ltd (BNR)

US · Healthcare · Diagnostics & Research

$8.97+1.47%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$107.9M

Revenue YoY

-18.9%

Net profit

$-17.5M

Profit YoY

-29.4%

EPS

$-0.21

Net margin

-16.2%

Key statistics

Market cap

$93.9M

Forward P/E

0.0

P/B

1.23

Book value

$7.27

EPS (TTM)

$-0.83

52-week high

$41.72

52-week low

$6.00

50-day MA

$9.71

200-day MA

$17.73

Beta

1.33

Analyst view

Analysts rate Burning Rock Biotech Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.03.

Shareholding

Insiders

4.01%

Institutions

46.86%

Largest institutional holders

Fund	Stake
Kynam Capital Management, LP	11.64%
CRCM LP	2.67%
Renaissance Technologies Corp	0.34%
Amova Asset Management Americas, Inc	0.29%
Sumitomo Mitsui Trust Group Inc	0.29%
Bank of America Corp	0.28%
HSG Holding Ltd	0.20%
Redwood Wealth Management Group LLC	0.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Burning Rock Biotech Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.